News

AliveAndKickn and OptraHEALTH partner to educate Lynch Syndrome patients globally.

San Jose, CA, October 25, 2020: OptraHEALTH^® has partnered with AliveAndKickn, a Lynch Syndrome hereditary cancer advocacy organization to implement the GeneFAX™ KnowledgeBOT on the AliveAndKickn website to help educate and make a difference in the lives of the individuals with Lynch syndrome. Lynch syndrome is a genetic condition that increases a person's risk for certain cancers. It is the most common inherited cause of colorectal and endometrial cancers. 1 in 279 individuals has a Lynch syndrome genetic mutation affecting millions of individuals worldwide.

San Jose, CA, September 10, 2020: OptraHEALTH^®, a leading data-driven intelligence company today announced that the United States Patent and Trademark Office(USPTO) has granted the patent to OptraHEALTH for healthcare AI applications with machine assisted process for health information handling.

San Jose, Calif, January 21st, 2020: OptraHEALTH^®,today announced that GeneFAX™, a conversational Genetic ChatBOT platform powered by Microsoft Azure AI, is now available as GeneFAX™ Pro on Microsoft Azure Marketplace ,online store providing applications and services for use on Azure.

San Jose, CA, and St. Petersburg, FL, November 5th, 2019: OptraHEALTH^®  and InformedDNA^® today announced that they will partner  to offer access to InformedDNA’s board-certified genetic counselors through GeneFAX’s AI-enabled CounselorConnect platform.

Patients to understand more about their genetic health through HIPPA Compliant GeneFAX™ ChatBOT on just a click

WASHINGTON (GenomeWeb) – This week, Optra Health, maker of the iPhronesis artificial intelligence platform for automated review of genetics literature and data, stepped into the consumer realm by introducing OptraGuru, an AI-based clinical report interpretation and guidance system.

SAN JOSE, Calif., Feb 20, 2018 (BUSINESS WIRE): OptraHEALTH^®, today announced the introduction of a revolutionary new business solution—OptraGURU™. OptraGuru harnesses vast stores of genetic data

OptraHEALTH^® today announced the introduction of a revolutionary new business solution—OptraGURU™. OptraGuru harnesses vast stores of genetic data locked away in corporate and public data silos, combines it with leading edge artificial intelligence and conversational technologies like Amazon Alexa to give genetic testing organizations the ability to offer a ‘round-the-clock’

Phoenix, USA

Gauri Naik

Optra Systems Inc., USA

Gauri Naik

Optra Systems Inc., USA

A company called OptraHEALTH^®, announced what it calls a revolutionary new business solution — OptraGURU — which harnesses genetic data from corporate and public data silos, and combines it with AI and conversational technologies like Amazon Alexa, to give genetic testing organizations the ability to offer a personalized and engaging service to their consumers. Also, the service is made to help genetic counselors and scientists, as well.

San Jose, CA: A few weeks back, the digital healthcare company Optra Health announced the launch of OptraGURU, its newest platform that leverages the AI tech of its iPhronesis offering with Amazon Alexa’s natural language skills. What does that nearly run-on sentence really mean? This news marks a mash-up of 3 of our 2018 Trends and points to a revolution in the way everyday people understand and engage with their genetic information.

Myriad Genetics, Inc. MYGN recently announced a collaboration with OptraHEALTH with the aim of implementing a cognitive ChatBOT, Gene. The AI-powered ChatBOT will provide genetic and financial assistance information to prospective patients of hereditary cancer.

SALT LAKE CITY, July 06, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™  to provide genetic and financial assistance information to prospective patients. 

SALT LAKE CITY, July 06, 2020 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™  to provide genetic and financial assistance information to prospective patients. 

Genetic diseases that run-in families predicate that other family members may require genetic testing -- GeneFAX™ CascadeBOT enables just that. GeneFAX™ InsuranceBOT addresses all aspects of health insurance and genetic testing. GeneFAX™ now also available on other social media apps

OptraHEALTH^®,today announced that GeneFAX™, a conversational Genetic ChatBOT platform powered by Microsoft Azure AI, is now available as GeneFAX™ Pro on Microsoft Azure Marketplace ,online store providing applications and services for use on Azure.

Patients gain additional access to expert genetic counseling from anywhere in the U.S. through the GeneFAX™ AI Platform

Press Release

Patients gain additional access to expert genetic counseling from anywhere in the U.S. through the GeneFAX™ AI Platform

Press Release

OptraHEALTH, the leading data-driven intelligence company, today announced that Dr. Gauri Naik, Founder & CEO, has received the prestigious ‘Women Entrepreneur 2019’ Award from DMA in association with Government of India.

Press Release

OptraHEALTH launches world first digital genetic companion on Android. Powered by the most advanced conversational AI technologies, GeneFAX™ allows users to get answers about genetics and genetic testing in a very simple, succinct and easy to understand manner.

Press Release

OptraHEALTH^®, which produces AI-driven iPhronesis analysis platform for healthcare and life sciences clients, today announced the launch of a new genetics-focused product specially designed for consumers, genetic counselors, and other genomics researchers.

iPhronesis Knowledge Automation Platform Uses Cognitive Crawling, Deep Machine Learning and Advanced Natural Language Processing to Help Automate Data Curation, Variant Classification and Clinical Reporting; Visit Optra Health at ACMG Clinical Genetics Annual Meeting